Hirulog-1 reduces expression of platelet-derived growth factor in neointima of rat carotid artery induced by balloon catheter injury

Journal of Vascular Research

Volumn 37, Issue 2, 2000, Pages 82-92

  Xue, Mengzhou ^a   Fenton II, John W ^b   Shen, Garry X ^a,c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Department of Health ^*  (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Balloon injury; Hirulog 1; Neointima; Platelet derived growth factor; Rat carotid artery

Indexed keywords

HIRULOG; PLATELET DERIVED GROWTH FACTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY INJURY; ARTERY INTIMA; ARTERY OCCLUSION; ARTICLE; BALLOON CATHETER; CAROTID ARTERY; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SCANNING ELECTRON MICROSCOPY;

EID: 0034037776     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000025719     Document Type: Article

References (48)

1. Fenton JW II: Thrombin functions and anti-thrombotic intervention. Thromb Haemost 1995;74:493-498.
2. Shen G: Vascular cell-derived fibrinolytic regulators and atherothrombotic vascular disorders (review), Int J Mol Med 1998;1:399-408.
3. Ross R, Raines EW, Bowen-Pope D: The biology of platelet-derived growth factor. Cell 1986; 46:155-169.
4. Libby P. Schwartz D, Brogi E, Tanaka H, Clinton SK: A cascade model for restenosis. A special case of atherosclerosis progression. Circulation 1992;86(suppl III):47-52.
5. Clowes AW, Reidy MA: Prevention of stenosis after vascular reconstruction: Pharmacologic control of intimal hyperplasia - A review. J Vasc Surg 1991;13:885-891.
6. Serruys PW, Herrman JP, Simon R, Rutsch W, Bode C, Laarman GJ, van Dijk R, van den Boss AA, Umans VAW, Fox KAA, Close P, Deckers JP, for Helvetica Investigators: A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995;333:757-763.
7. Gallo R, Padurean A, Toschi V, Bichler J, Fallon JT, Chesebro JH, Fuster V, Badiman JJ: Prolonged thrombin inhibition reduces restenosis after balloon angioplasty in porcine coronary arteries. Circulation 1998;97:581-588.
8. Thome LM, Gimple LW, Bachhuber BG, McNamara CA, Ragosta M, Gertz SD, Powers ER, Owen GK, Humphries JE, Sarembock IJ: Early plus delayed hirudin reduces restenosis in the atherosclerotic rabbit more than early administration alone: Potential implication for dosing of antithrombin agents. Circulation 1998;98:2301-2306.
9. Antman EM, for the TIMI 9B Investigators: Hirudin in acute myocardial infarction thrombolysis and thrombin inhibition in myocardial (TIMI) 9B trial. Circulation 1996;94:911-921.
10. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) Ila Investigators: Randomized trial intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994;90:1631-1637.
11. Neuhaus KL, von Essen R, Tebbe U, Jessel A, Heinrichs H, Maurer W, Doring W, Harmjanz D, Kotter V, Kalhammer E, Simon H, Horacek T: Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK). Circulation 1994;90:1638-1642.
12. Maraganore JM, Bourdon P, Jablonski J. Ramaehandran KL, Fenton JW II: Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990;29:7095-7101.
13. Lidon RM, Theroux P, Juncau M, Adelman B, Maraganore J: Initial experience with a direct antithrombin, hirulog in unstable angina. Anticoagulant, antithrombotic, and clinical effects. Circulation 1993;88:1495-1501.
14. Lidon RM, Theroux P, Lesperance J, Adelman B, Bonan R, Duval D, Levesque J: A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation 1994;89:1567-1572.
15. Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, Maraganore J, Deutsch E, Adelman B: Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postin-farction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 1995;333:764-769.
16. Hamelink JK, Tang DB, Barr CF, Jackson MR, Reid TJ, Gomez ER, Alving BM: Inhibition of platelet deposition by combined hirulog and aspirin in a rat carotid endarterectomy model. J Vasc Surg 1995;21:492-498.
17. Jackson MR, Reid TJ, Tang DB, O'Donnell SD, Gomez ER, Alving BM: Antithrombotic effects of hirulog in a rat carotid endarterectomy model. J Surg Res 1996;60:15-22.
18. Sarembock IJ, Gertz SD, Thome LM, McCoy KW, Ragosta M, Power ER, Maraganore JM, Gimple LW: Effectiveness of hirulog in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. J Vasc Res 1996;33:308-314.
19. Muller DW, Gordon D, Topol EJ, Levy RJ, Golomb G: Sustained-release local hirulog therapy decreases early thrombosis but not neointimal thickening after arterial stenting. Am Heart J 1996;131:211-218.
20. Banai S, Wolfy, Golomb G, Pearle A, Waltenberger J, Fishbein I, Schneider A, Gazit A, Perez L, Huber R, Lazarovichi G, Rabinovich L, Levitzki A, Gertz SD: PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointima formation after balloon angioplasty in swine. Circulation 1998;97:1960-1969.
21. Savani RC, Turley EA: The role of hyaluronan and its receptor in restenosis after balloon angioplasty: Development of a potential therapy, Int J Tissue React 1995;17:141-151.
22. Golomb G, Fishbein I, Banai S, Mishialy D, Moscovitz D, Gertz D, Poradosu E, Levitzki A: Controlled delivery of a tyrphostin inhibits intimal hyperplasia in a rat carotid artery injured model. Atherosclerosis 1996;125:171-182.
23. Joy DC, Pawley JB: High resolution scanning electron microscopy. Ultramicroscopy 1992; 47:80-100.
24. Lavee J, Martinowitz U, Mohr R, Goor DA, Golan M, Langsam J, Malik Z, Savion N: The effect of transfusion of fresh whole blood versus platelet concentrates after cardiac operations. A scanning electron microscope study of platelet aggregation on extracellular matrix. J Thorac Cardiovas Surg 1989;97:204-212.
25. Burton PB, Quirke P, Sorensen CM, Nehlsen-Cannarella SL, Bailey LL, Knight DE: Growth factor expression during rat development: A comparison of TGF-beta-3, TGF-alpha, bFGF, PDGF and PDGF-R. Int J Exp Pathol 1993; 74:87-96.
26. Wei GL, Krasinski K, Kearney M, Isner JM, Walsh K, Andres V: Temporally and spatially coordinated expression of cell cycle regulatory factors after angioplasty. Circ Res 1997;80: 418-426.
27. Gonzales C, Lin RC, Chesselet MF: Relative sparing of GABAergic interneurons in the striatum of gerbils with ischemia-induced lesions. Neurosci Lett 1992;135:53-58.
28. Kuge Y, Minematsu K, Yamaguchi T, Miyake Y: Nylon monofilament for intraluminal middle cerebral arten occlusion in rats. Stroke 1995;26:1655-1658.
29. Reid TJ III, Alving BM: A quantitative thrombin time for determining levels of hirudin and hirulog. Thromb Haemost 1993;70:608-616.
30. Stenberg PE, Barrie RJ, Pestina TI, Steward SA, Arnold JT, Murti AK, Hutson NK, Jackson CK: Prolonged bleeding time with defective platelet filopodia formation in the Wistar-Furth rat. Blood 1998;91:1599-1608.
31. Stockmans F, Deberdt W, Nystrom A, Nystrom E, Stassen JM, Vermylen J, Deckmyn H: Inhibitory effect of piracetam on platelet-rich thrombus formation in an animal model. Thromb Haemost 1998;79:222-227.
32. Ryan TJ, Fajxon DP, Gunnar RM, Kennedy JW, King SB III, Loop FD, Peterson KL, Reeves TJ, Williams DO, Winters WL Jr, Fisch C, DeSanctis RW, Dodge HT, Weinberg SL: Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol 1988;12:529-545.
33. Safian RD, Gelbfish JS, Erny RE, Schnitt SJ, Schmidt DA, Bairn DS: Coronary atherectomy, Clinical, angiographie, and histological findings and observations regarding potential mechanisms (comments). Circulation 1990;82: 69-79.
34. Narins CR, Holmes DR, Topol EJ: A call for provisional stenting: The balloon is back. Circulation 1998;97:1298-1305.
35. Popma JJ, Satler LF, Pichard AD, Kent KM, Campell A, Chuang YC, Clark C. Merritt AJ, Bucher TA, Leon MB: Vascular complications after balloon and new device angioplasty. Circulation 1993;88:1569-1578.
36. Rade JJ, Schulick AH, Virmani R, Dichek DA: Local adenoviral-mediatcd expression of recombinant hirudin reduces neointima formation after arterial injury. Nat Med 1996;2:293-298.
37. Van den Bos AA, Deckers JW, Heyndrickx GR, Laarman GJ, Suryapranata H, Zijlstra F, Close P, Rijnierse JJ, Buller HR, Serruys PW: Safety and efficacy of recombinant hirudin (CGP-39393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation 1993;88:2058-2066.
38. Topol EJ, Fuster V, Harringto RA, Califf RM, Kleiman NS, Kereiakes DJ, Cohen M, Chapekis A, Gold HK, Tannembaum MA, Rao AK, Debowey D,Schwartz D, Hanis M, Chesebro J: Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial. Circulation 1994;89:1557-1566.
39. Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haugland JM, Anderson JL, Sharaf BL, Edwards SJ, Williams DO, Braunwald E, for the TIMI 5 Investigators: A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 Trial. J Am Coll Cardiol 1994;23:993-1003.
40. Lee LV, for the TIMI 6 Investigators: Initial experience with hirudin and streptokinase in acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 6 Trial. Am J Cardiol 1995;75:7-13.
41. Adgey AA: Bleeding complications with new antithrombotics used in ischaemic heart disease. Haemostasis 1996;26:237-246.
42. Ishiwata S, Tukada T, Nakanishi S, Nishiyama S, Seki A: Postangioplasty restenosis: Platelet activation and the coagulation-fibrinolytic system as possible factors in the pathogenesis of restenosis. Am Heart J 1997;133:387-392.
43. Tsakiris DA, Tschopl M, Jager K, Haefeli WE, Wolf F, Marbet GA: Circulating cell adhesion molecules and endothelial markers before and after transluminal angioplasty in peripheral arterial occlusive disease. Atherosclerosis 1999; 142:193-200.
44. Walker LN, Bown-Pope DF, Ross R, Reidy MA: Production of platelet-derived growth factor-like molecules by cultured arterial smooth muscle cells accompanies proliferation after arterial injury. Proc Natl Acad Sci USA 1986;83: 7311-7315.
45. Ferns GA, Raines EW, Sprugel KLH, Motani AS, Reidy MA, Ross R: Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 1991; 253:1129-1132.
46. Liu LY, Dai E, Hobman ML, Kolodziejczk MD, Lucas A: Animal models of restenosis: Myth or reality. Curr Pharmaceut Design 1996; 2:553-584.
47. Fenton JW II: Leeches to hirulogs and other thrombin-directed antithrombotics. Hematol Oncol Clin North Am 1992;6:1121-1129.
48. Ren S, Fenton JW, Maraganore JM, Angel A, Shen GX: Inhibition by hirulog-1 of generation of plasminogen activator inhibitor-1 from vascular smooth muscle cells induced by thrombin. J Cardiovasc Pharmacol 1997;29:337-342.